Assessment of sTREM-1 as a Diagnostic Marker in Patients With Neutropenic Fever

Neutropenic Fever Clinical Trial

Official title: Assessment of sTREM-1 as a Diagnostic Marker in Patients With Neutropenic Fever

Status Completed

Clinical Trial Summary

The soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) was an established biomarker useful for infection in non-neutropenic patients. In this study, we tested sTREM-1 in the patients with neutropenic fever. Pro-calcitonin (PCT) and C-reactive protein (CRP) were also measured. We planned to investigate and explore the role of sTREM-1 in early diagnosis of infection in patients with neutropenic fever.

Clinical Trial Description

Patients with hematological malignancies developed neutropenia after chemotherapy. We checked the serum level of sTREM-1 in patients with neutropenic fever. Those patients were classified to 2 groups: documented infection or low likelihood of infection. Their sTREM-1 level was measured and was compared with other biomarker such as CRP and procalcitonin. The value of sTREM-1 for diagnosis of infection in patients with neutropenic fever was thus evaluated. ;

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

• Febrile Neutropenia
• Fever
• Neutropenic Fever

• NCT number: NCT01034059
• Study type: Observational
• Source: National Taiwan University Hospital
• Status: Completed
• Phase: N/A
• Start date: October 2008
• Completion date: June 2009